Cultured bovine aortic endothelial cells (BAEC) released endothelin-1 (ET-1) i n the culture medium in a timedependent fashion. Coincubation of fMLP-activated human polymorphonuclear leukocytes (PMN) with BAEC caused a fast (maximal activity was reached within 15 minutes) and cell number-dependent disappearance of ET-1 from the medium. This effect was direct t o ET-1, because it was also present when PMN were incubated with the synthetic peptide in the absence of BAEC. PMN-dependent disappearance of ET-1 was associated with loss of constrictor activity on isolated rabbit aorta. PMN-released products were responsible for ET-1 degrading activity, because supernatants of activated PMN were equally effective as the intact cells. Resting PMN, in the same time frame, were uneffective. Eglin NDOTHELIN-1 (ET-l), a 21-amino acid peptide re-E cently isolated from the medium of cultured endothelial cells,' represents one of the most potent vasoconstrictors known. Relatively high blood levels of this peptide have been found in different pathologies, including uremia,'~~ acute myocardial infarction: and acute renal failure?
MATERIALS AND METHODS
PMN were isolated from venous blood of healthy volunteers according to the method of B0yum" and resuspended in Hepes-Tyrode buffer supplemented with 0.1% bovine serum albumin (BSA). BAEC were cultured in Modified Eagle's Medium (MEM) supplemented with 15% fetal bovine serum (GIBCOEurope, Paisley, UK) as described," and used between three and 10 passages. For the experiments described, bovine aortic endothelial cells (BAEC) detached by brief exposure to trypsin (0.25%)-EDTA (0.022%), were plated and grown to confluence in 24-well plates.
Aliquots of PMN (0.37 to 3 x 1@ cells in a final volume of 300 FL) were added to each BAEC well in the presence of fibrinogen (Kabi Vitrum, Stockholm, Sweden) and cytochalasin B (0.38 mg/mL and 2.5 Fg/mL, respectively). After Cells.
Eiperimentalprocedures.
C, a potent blocker of PMN-derived elastase and cathepsin G, reversed the ET-1 inhibitory activity of fMLP-stimulated PMN and of their supernatant. Direct addition of elastase and cathepsin G t o synthetic ET-1 destroyed its immunoreactivity and this effect was blocked by eglin C. High-performance liquid chromatography (HPLC) analysis supported the hypothesis that ET-1 degradation by PMN was due t o enzymatic proteolysis. These data provide evidence that activated PMN are able t o degrade ET-1 through the release of proteases.
Because physiologic concentrations of PMN can destroy high amounts (up t o 100 nmol/L) of ET-1 within a few minutes, we propose that this mechanism of ET-1 inactivation has biologic relevance. 0 1991 by The American Society of Hematology.
addition of lo-' mol/L M L P (Sigma Chemical, St Louis, MO) or the equivalent volume of isotonic saline, plates were incubated at 37°C for the times indicated (15 to 180 minutes). At the end of the incubation, the assay medium was collected and centrifuged at 12,OOQg for 1 minute. Supernatants were then collected and stored at -20°C for ET-1 determination by radioimmunoassay.
In some experiments, either PMN (in the presence or absence of mol/L M L P ) or PMN-derived supernatants were incubated (15 minutes at 37°C) with different concentrations of synthetic ET-1 (1 to 100 nmol/L). Samples were then centrifuged and the supernatants collected for measuring ET-1 recovery. PMN-derived supernatants were prepared by centrifuging 1.5 x lo7 cells/mL that had been previously incubated (37°C for 15 minutes) with 3 x lo-' mol/L M L P or isotonic saline. In some experiments, supernatants were obtained following PMN stimulation with platelet-activating factor (PAF), leukotriene B, (LTB,), or zymosan-activated serum ( U S ) . ET-1 degrading activity of PMN and PMN-derived supernatants was evaluated in presence of the following protease inhibitors: leupeptin (Sigma), phosphoramidon (Boehringer, Mannheim, Germany), eglin C (a generous gift of Dr H.P. Schnebli, CibaGeigy, Basel, Switzerland), and EDTA (Merck, Darmstadt, Germany). These compounds were added to PMN or PMN-derived supernatants before addition of synthetic ET-1 (100 nmol/L). Samples were then incubated at 3 P C for 15 minutes, centrifuged, and subsequently assayed for ET-1 recovery.
In a set of experiments, ET-1 (100 nmol/L) was incubated (15 to 180 minutes at 3PC) in the absence or presence of 10 to 200 nmol/L purified human elastase Studies with purijied proteases. A radioimmunoassay technique for endothelin was developed. The assay used 2,000 dpm of lZSI-ET-l (Novabiochem, Laufelfingen, Switzerland) and an anti-ET-1 serum (Peninsula, Belmont, CA) diluted 1:100,ooO that showed 100% of cross-reactivitywith both ET-1 and ET-2,9% with ET-3, 1.5% with big ET-l(1-38), and 0.83% with big ET-l(1-39). Aliquots (100 pL) of unextracted incubation media were incubated at 4°C for 72 hours in 2.5 ml of 0.025 mol/L Tris-phosphate-HC1 (pH 9). Separation of the antibody-bound ET-1 from free ligand was achieved by rapidly adding 50 pL of charcoal-treated human plasma and 100 p L of a charcoal suspension (100 mg/mL) and subsequent centrifugation at 3,000 rpm for 10 minutes at 4°C. Supernatant solutions (antibody-bound ET-1) and pellets (charcoaladsorbed ET-1) were counted in a Beckman gamma counter (Fullerton, CA). The IC,, value (concentration of unlabeled ET-1 that reduced by 50% the bound to free ratio of the homologous tracer) was 2.4 fmol/mL. The least detectable concentration that could be measured with 95% confidence (ie, 2 SD at zero) was 0.2 fmol/mL. Validation of ET-1 measurements was obtained by dilution and recovery studies.
From the University of
In the experiments reported here, the recovery of synthetic ET-1 after 15 minutes of incubation averaged 80%. This was considered the maximal recovery (100%) and the results are referred to this value. This reduction of ET-1 recovery did not further decrease with time (up to 180 minutes) and probably reflected an aspecific ET-1 binding to plastic surfaces.
Male albino rabbits (2.0 to 2.2 kg; Charles River, Calco, Italy) were killed by excess urethane anesthesia and exsanguinated. The descending thoracic aorta was isolated, cut as spirals of approximately 30 mm in length, and the segments were mounted in an organ bath (20 mL) containing oxygenated (OJCO,: 95%/5%) Krebs-bicarbonate solution at 3 P C under a load of 2 g. Samples (1 mL) containing synthetic ET-1 (100 nmol/L) preincubated (15 minutes at 37°C) with or without lo-' mol/L fMLP-activated PMN (3 x lo6) were spun down and supernatants (200 pL) added to the aorta segments; the response to ET-1 (final concentration, 1 nmol/L) was recorded during 20 minutes. Changes in the length of tissues were measured isotonically and the data were expressed as millimeters of contraction. All the preparations showed the same maximal contractile response to
ET-1 (400 nmol/L) was incubated (15 minutes at 37°C) with 100 nmol/L cathepsin G or elastase or control buffer, in the presence or absence of 25 pg/mL eglin C. Samples were applied to SEP-PAK C18 cartridges (Waters, Milford, MA) pretreated with 10 mL methanol and 10 mL water. After washing with 10 mL of trifluoroacetic acid (TFA, O.l%), the peptides were eluted with 3 mL of acetonitrile (60%) in 0.1% TFA. The eluted samples were concentrated by evaporation under vacuum and reconstituted in 0.15 mL of 30% acetonitrile in 0.1% TFA and subjected to reverse-phase HPLC analysis by using a p-bondapack C18 column (0.39 X 30 cm; Waters). Elution was performed by using a binary gradient consisting of 10% acetonitrile in 0.1% TFA (solvent A) and 90% acetonitrile in 0.1% TFA (solvent B). The elution profile incorporated a linear gradient from 10% to 80% solvent B in 60 minutes at a flow rate of 1 mL/min. Eluates were monitored by absorbance at 220 nm. Synthetic ET-1 eluted as a single peak with a retention Bioassay of vasoconstrictor activiy.
High-performance liquid chromatography (HPLC) analysis.
time of 28.2 2 0.2 minutes (mean * SD, n = 4). ET-1 extraction by SEP-PAK C18 cartridges caused the appearance of an additional peak eluting at 26.6 f 0.2 minutes. Since both peaks were recognized by ET-1 antiserum, the peptide eluting at 26.6 minutes is likely to represent an aggregated form of ET-1, as recently r e~0 r t e d . l~
RESULTS

Effect of PMN on endothelin immunoreactivity (ET-ir)
released by cultured BAEC. BAEC released ET-ir in a time-dependent fashion (Fig 1) . When increasing concentrations of fMLP-activated PMN were added, the amount of ET-ir measured in the medium was dramatically reduced (Fig 1) . With 1.5 to 3 x lo6 PMN, ET-ir was barely detectable at 15 minutes. fMLP (lo-' mol/L) added per se to BAEC did not significantly alter ET-ir content in the medium (not shown). The addition of unstimulated PMN (3 x lo6) to BAEC did not significantly reduce the amount of ET-ir measured at 15 minutes and 2 hours of incubation (115% r 16% and 90% * 17% of the amount of ET-ir measured in the absence of PMN, respectively; means r SEM of three separate experiments).
Superoxide dismutase (10 to 100 U/mL), a superoxide anion scavenger, did not affect the reduction of BAECderived ET-ir by stimulated PMN (3 X lo6 cells/well) up to 3 hours of incubation (data not shown).
Effect of PMN on synthetic ET-1. We next studied whether ET-1 reduction in BAEC culture medium was due to a direct effect of PMN on this peptide. For this purpose, synthetic ET-1 was incubated with fMLP-activated PMN. The synthetic peptide was degraded to an extent dependent on PMN number (Fig 2) . At a physiological concentration (3 x lo6), activated PMN were able to destroy up to 100 nmol/L ET-1 within 15 minutes. In the same time frame, For unstimulated PMN (3 x lo6) did not significantly change ET-1 recovery (1 to 100 nmol/L; data not shown).
Effect of PMN on ET-1 biologic activity. Functional studies performed on isolated rabbit aorta confirmed that PMN-induced reduction of ET-ir corresponded to a loss of biologic activity. ET-1 (100 nmol/L) was incubated (15 minutes at 37°C) with fMLP (lO-'mol/L) in the presence or absence of PMN (3 x 10'); samples were centrifuged and supernatants collected. Supernatants that had been incubated in the absence of PMN induced a slow and longlasting contraction; conversely, no response was observed following ET-1 preincubation with activated PMN (Fig 3) . Furthermore, the contracting activity of ET-1 was unaffected when ET-1 and supernatants of activated PMN were added simultaneously to the vessel. The supernatant of activated PMN did not modify per se the basal tone (data not shown).
Effect of PMN-derived supematants on synthetic ET-1. We then investigated whether intact PMN were required for ET-1 degrading activity. When supernatants of fMLPactivated PMN (3 x lo6) were incubated for 15 minutes with 100 nmol/L ET-1, the peptide was degraded (3% f 2% of recovery) as effectively as when the same number of intact cells was used (5% +-1% of recovery). Supernatants of PMN stimulated by fMLP (lo-' mol/L) in the absence of cytochalasin B did not reduce ET-1 (100 nmol/L) recovery (95% f 3% v 5% 2 2% in absence or presence of cytochalasin B, respectively), suggesting that extracellular enzymatic release was necessary to cause ET-1 disappearance. Supernatants of PMN stimulated by other agonists were tested for their ability to degrade ET-1. When PAF mol/L), LTB, (3 x lo-' mol/L), and ZAS (5%) were used, PMN supernatants reduced ET-1 (100 nmol/L) recovery to, respectively, 60% 2 4%, 62% f 3%, and 75% f 3% of the total amount of ET-1 added, at 15 minutes of incuba- tion; longer incubation times (up to 60 minutes) did not modify the recovery. None of these compounds was effective in the absence of cytochalasin B (not shown).
Effect of PMN-derived proteolytic enzymes on synthetic ET-1. In an attempt to define whether PMN derived proteases were responsible for ET-1 degradation, different protease inhibitors were used. Leupeptin (2 x lo-, mol/L), phosphoramidon mol/L), and EDTA (2 x lO-'moI/L) did not affect ET-1 (100 nmol/L) degradation induced by fMLP-activated PMN (3 x lo6) or their supernatants. In contrast, eglin C (25 kg/mL), a serine protease inhibitor," reversed the effect of both intact PMN and supernatants in the same experimental conditions ( Table 1) .
Incubation of 100 nmol/L ET-1 with two PMN-derived serine proteases, elastase and cathepsin G (10 to 200 nmol/L), for different times (15 to 180 minutes), resulted in a dose-dependent reduction of ET-1 recovery (Fig 4) , which was reversed by 25 pg/mL eglin C (Fig 5) . 
Effect of cathepsin G and elastase on ET-I in whole blood. To assess whether PMN-derived proteolytic enzymes were able to degrade ET-1 in the presence of naturally occurring plasma antiproteases, elastase and cathepsin G (100 nmol/L) were incubated in whole blood with 100 nmol/L synthetic ET-1 for different times. Cathepsin G induced consistent and time-dependent ET-1 degradation, while elastase had no effect (Fig 6) . Only a slight decrease of ET-1 recovery occurred during the incubation in whole blood (Fig 6) .
To collect further evidence of ET-l degradation by PMN, synthetic ET-l was incubated with purified cathepsin G and elastase and ET-1 recovery was evaluated by HPLC analysis. Extraction of synthetic ET-1 by SEP-PAK C18 cartridges resulted in the appearance of two different peaks (Fig 7A) , both of which reacted with ET-1 antiserum (not shown). After incubation of 400 pmol ET-1 with 100 nmol/L cathepsin G (15 minutes at 37"C), the two peaks disappeared, while a major peak, with a retention time of 5.5 minutes, was observed. Eglin C (25 pg/mL) prevented ET-1 degradation Anahsis of ET-I degradation by HPLC.
-
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T control elastase cathepsin G by cathepsin G (Fig 7B) . Similar results were obtained with 100 nmol/L elastase (not shown).
DISCUSSION
In this report, we demonstrate that short-term (15-minute) coincubation of BAEC with MLP-activated PMN dramatically reduced ET-ir in the culture medium. This effect was not due to inhibition of ET-1 synthesis and release by endothelial cells, since it was also apparent when incubating synthetic ET-1 with activated PMN. Furthermore, synthetic ET-1 disappearance was also present when supernatants of activated PMN were used, thus indicating that ET-1 degrading activity (or at least a large part of it) was not cell-associated or due to PMN uptake of the peptide. M L P was the most potent inducer of ET-1 degrading activity by PMN, but also PAF, LTB,, and Z A S were partially effective. The observation that eglin C, a powerful serine protease inhibitor," was able to reverse the inhibitory action of PMN supernatants and that purified elastase and cathepsin G could effectively destroy ET-1, or presence (-) of eglin C (25 pg/mL), was subsequently extracted and analyzed by HPLC. strongly suggests that PMN-derived serine proteases are responsible for ET-1 degrading activity. Noteworthy, supernatants of PMN stimulated in the absence of cytochalasin B, a condition associated with low levels of PMN enzymatic release in vitro,16 did not cause ET-1 degradation. However, the release by PMN of proteolytic enzymes in inflammatory sited7 may play an active role in ET-1 degradation in vivo.
Other investigators recently reported that ET-1 is particularly sensitive to the hydrolysis induced by the kidney neutral end~peptidase.'~~'~ This enzyme is also present on PMN membrane. However, we found that phosphoramidon, a specific neutral endopeptidase inhibitor, did not affect PMN-derived ET-1 degrading activity. Therefore, it is unlikely that this enzyme (either cell-associated or shedded in the medium) could be responsible of ET-1 destruction, at least under the present experimental conditions. ET-1 degradation by PMN-derived proteolytic enzymes evaluated by radioimmunoassay was confirmed by the results showing loss of ET-1 vasoconstrictor activity following exposure of the peptide to activated PMN (Fig 3) . Moreover, HPLC analysis indicated that proteolytic cleavage products may be generated on PMN activation (Fig 7) , as recently
The observation reported here that activated PMN could destroy ET-1 activity might have biologic relevance. Indeed, physiologic concentrations of PMN are able to degrade a large quantity of this peptide within a few minutes (Figs 1  and 2 ).
Although naturally occurring protease inhibitors might limit the ability of PMN-derived proteases" to degrade ET-1, data reported here indicate that cathepsin G-dependent degradation of ET-1 is also evident in whole blood, ie, in the presence of plasma protease inhibitors. At variance with cathepsin G, elastase produced only little, if any, ET-1 degradation. This is likely to reflect the fact that the plasma protease inhibitors &,-protease inhibitor and q-macroglobulin bind with higher affinity to elastase than to cathepsin G.".= Furthermore, cathepsin G ability to degrade ET-1 might be scarcely impaired in whole blood, since its specific inhibitor, a,-antichimotrypsin," is present at relatively low concentrations.= Experiments performed in whole blood indicated that ET-1 recovery did not significantly decrease with time (up to 180 minutes); these results support the in vivo findings that ET-1 is cleared from the circulation mainly by removal into parenchymal tissues.=
The results of this work suggest that under conditions associated with the release of proteolytic enzymes by activated PMN, ET-1 may be degraded with loss of biologic activity. In the case of acute inflammatory reaction and in tissue ischemia, PMN adhere to the endothelium in response to chemotactic stimuli?6 The local release of ET-1 induced by inflammatory mediators6s7 and the consequent vasoconstriction and inhibition of vascular permeability' could therefore be reduced or abolished by the action of PMN-derived proteases. This effect could be further amplified by the release of PGI, from endothelial cells in response to the interaction with activated PMN."
